Combination therapy with bioengineered miR-34a prodrug and doxorubicin synergistically suppresses osteosarcoma growth

Biochemical Pharmacology

Volumn 98, Issue 4, 2015, Pages 602-613

  Zhao, Yong ^a,b   Tu, Mei Juan ^b   Yu, Yi Feng ^a   Wang, Wei Peng ^b   Chen, Qiu Xia ^b   Qiu, Jing Xin ^c   Yu, Ai Xi ^a   Yu, Ai Ming ^b  

^a WUHAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Doxorubicin; miR 34a; Orthotopic tumor; Osteosarcoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLIN DEPENDENT KINASE 6; DOXORUBICIN; MICRORNA 34A; PROTEIN; SCATTER FACTOR RECEPTOR; SIRTUIN 1; UREA; GROWTH INHIBITOR; MICRORNA; MIRN34 MICRORNA, HUMAN; PRODRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; CELL INVASION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG POTENTIATION; DRUG SAFETY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; MOUSE MODEL; MULTIPLE DRUG DOSE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; REPEATED DRUG DOSE; RNA INTERFERENCE; TUMOR XENOGRAFT; UREA NITROGEN BLOOD LEVEL; ANIMAL; BIOENGINEERING; BONE NEOPLASMS; COMBINATION DRUG THERAPY; DRUG SCREENING; MALE; NUDE MOUSE; PATHOLOGY; PREVENTION AND CONTROL; PROCEDURES; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; BIOENGINEERING; BONE NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG THERAPY, COMBINATION; GROWTH INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; PRODRUGS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84947223452     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.10.015     Document Type: Article

References (53)

1. R. Gorlick, K. Janeway, S. Lessnick, R.L. Randall, N. Marina, and Committee COGBT Children's Oncology Group's 2013 blueprint for research: bone tumors Pediatr. Blood Cancer 60 2013 1009 1015
2. R.K. Rivera-Valentin, L. Zhu, and D.P. Hughes Bone sarcomas in pediatrics: progress in our understanding of tumor biology and implications for therapy Paediatr. Drugs 17 2015 257 271
3. L. Mirabello, R.J. Troisi, and S.A. Savage Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program Cancer 115 2009 1531 1543
4. L. Kager, A. Zoubek, U. Potschger, U. Kastner, S. Flege, B. Kempf-Bielack, and et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols J. Clin. Oncol. 21 2003 2011 2018
5. G. Bacci, M. Rocca, M. Salone, A. Balladelli, S. Ferrari, E. Palmerini, and et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions J. Surg. Oncol. 98 2008 415 420
6. P. Brennecke, M.J. Arlt, C. Campanile, K. Husmann, A. Gvozdenovic, T. Apuzzo, and et al. CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice Clin. Exp. Metastasis 31 2014 339 349
7. G. Cassinelli, C. Lanzi, M. Tortoreto, D. Cominetti, G. Petrangolini, E. Favini, and et al. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models Biochem. Pharmacol. 85 2013 1424 1432
8. B.A. Teicher Searching for molecular targets in sarcoma Biochem. Pharmacol. 84 2012 1 10
9. V. Ambros The functions of animal microRNAs Nature 431 2004 350 355
10. D.P. Bartel MicroRNAs target recognition and regulatory functions Cell 136 2009 215 233
11. A.M. Yu Role of microRNAs in the regulation of drug metabolism and disposition Expert Opin. Drug Metab. Toxicol. 5 2009 1513 1528
12. A.G. Bader, D. Brown, and M. Winkler The promise of microRNA replacement therapy Cancer Res. 70 2010 7027 7030
13. A.L. Kasinski, and F.J.E. Slack Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy Nat. Rev. Cancer 11 2011 849 864
14. H. Ling, M. Fabbri, and G.A. Calin MicroRNAs and other non-coding RNAs as targets for anticancer drug development Nat. Rev. Drug Discov. 12 2013 847 865
15. C. Welch, Y. Chen, and R.L. Stallings MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells Oncogene 26 2007 5017 5022
16. L. He, X. He, L.P. Lim, E. de Stanchina, Z. Xuan, Y. Liang, and et al. A microRNA component of the p53 tumour suppressor network Nature 447 2007 1130 1134
17. A. Tivnan, L. Tracey, P.G. Buckley, L.C. Alcock, A.M. Davidoff, and R.L. Stallings MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma BMC Cancer 11 2011 33
18. T.C. Chang, E.A. Wentzel, O.A. Kent, K. Ramachandran, M. Mullendore, K.H. Lee, and et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis Mol. Cell 26 2007 745 752
19. F. Sun, H. Fu, Q. Liu, Y. Tie, J. Zhu, R. Xing, and et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest FEBS Lett. 582 2008 1564 1568
20. C. Liu, K. Kelnar, B. Liu, X. Chen, T. Calhoun-Davis, H. Li, and et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44 Nat. Med. 17 2011 211 215
21. M. Yamakuchi, M. Ferlito, and C.J. Lowenstein miR-34a repression of SIRT1 regulates apoptosis Proc. Natl. Acad. Sci. U. S. A. 105 2008 13421 13426
22. R.L. Vinall, A.Z. Ripoll, S. Wang, C.X. Pan, W. deVere, and R.W. White MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status Int. J. Cancer 130 2012 2526 2538
23. X. Deng, M. Cao, J. Zhang, K. Hu, Z. Yin, Z. Zhou, and et al. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer Biomaterials 35 2014 4333 4344
24. K. Kelnar, H.J. Peltier, N. Leatherbury, J. Stoudemire, and A.G. Bader Quantification of therapeutic miRNA mimics in whole blood from non-human primates Anal. Chem. 86 2014 1534 1542
25. Y. Wang, L.S. Jia, W. Yuan, Z. Wu, H.B. Wang, T. Xu, and et al. Low miR-34a and miR-192 are associated with unfavorable prognosis in patients suffering from osteosarcoma Am. J. Transl. Res. 7 2015 111 119
26. X. Wu, D. Zhong, Q. Gao, W. Zhai, Z. Ding, and J. Wu MicroRNA-34a inhibits human osteosarcoma proliferation by downregulating ether a go-go 1 expression Int. J. Med. Sci. 10 2013 676 682
27. H. Zhao, B. Ma, Y. Wang, T. Han, L. Zheng, C. Sun, and et al. miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44 Oncol. Rep. 29 2013 1027 1036
28. K. Yan, J. Gao, T. Yang, Q. Ma, X. Qiu, Q. Fan, and et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo PLoS One 7 2012 e33778
29. C. Novello, L. Pazzaglia, A. Conti, I. Quattrini, S. Pollino, P. Perego, and et al. p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression PLoS One 9 2014 e114757
30. W.P. Wang, P.Y. Ho, Q.X. Chen, B. Addepalli, P.A. Limbach, M.M. Li, and et al. Bioengineering novel chimeric microRNA-34a for prodrug cancer therapy: high-yield expression and purification, and structural and functional characterization J. Pharmacol. Exp. Ther. 354 2015 131 141
31. Q.X. Chen, W.P. Wang, S. Zeng, S. Urayama, and A.M. Yu A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications Nucleic Acids Res. 43 2015 3857 3869
32. P.Y. Ho, A.M. Yu, Bioengineering noncoding RNAs for research and development. Wiley Interdiscip Rev RNA. (in submission).
33. M.M. Li, B. Addepalli, M.J. Tu, Q.X. Chen, W.P. Wang, P.A. Limbach, and et al. Chimeric microRNA-1291 biosynthesized efficiently in Escherichia coli is effective to reduce target gene expression in human carcinoma cells and improve chemosensitivity Drug Metab. Dispos. 43 2015 1129 1136
34. E. Tahover, Y.P. Patil, and A.A. Gabizon Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes Anticancer Drugs 26 2015 241 258
35. M. Schwebe, S. Ameling, E. Hammer, J.V. Monzel, K. Bonitz, S. Budde, and et al. Protective effects of endothelin receptor A and B inhibitors against doxorubicin-induced cardiomyopathy Biochem. Pharmacol. 94 2015 109 129
36. S. Granados-Principal, N. El-Azem, R. Pamplona, C. Ramirez-Tortosa, M. Pulido-Moran, L. Vera-Ramirez, and et al. Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer Biochem. Pharmacol. 90 2014 25 33
37. N. Tarasenko, S.M. Cutts, D.R. Phillips, G. Berkovitch-Luria, E. Bardugo-Nissim, M. Weitman, and et al. A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo Biochem. Pharmacol. 88 2014 158 168
38. T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
39. X. Li, Y.Z. Pan, G.M. Seigel, Z.H. Hu, M. Huang, and A.M. Yu Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells Biochem. Pharmacol. 81 2011 783 792
40. Y. Su, E.R. Wagner, Q. Luo, J. Huang, L. Chen, B.C. He, and et al. Insulin-like growth factor binding protein 5 suppresses tumor growth and metastasis of human osteosarcoma Oncogene 30 2011 3907 3917
41. P.D. Ottewell, J.K. Woodward, D.V. Lefley, C.A. Evans, R.E. Coleman, and I. Holen Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone Mol. Cancer Ther. 8 2009 2821 2832
42. H.H. Luu, Q. Kang, J.K. Park, W. Si, Q. Luo, W. Jiang, and et al. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis Clin. Exp. Metastasis 22 2005 319 329
43. A.B. Mohseny, I. Machado, Y. Cai, K.L. Schaefer, M. Serra, P.C. Hogendoorn, and et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease Lab. Invest. 91 2011 1195 1205
44. J. Yuan, C. Ossendorf, J.P. Szatkowski, J.T. Bronk, A. Maran, M. Yaszemski, and et al. Osteoblastic and osteolytic human osteosarcomas can be studied with a new xenograft mouse model producing spontaneous metastases Cancer Invest. 27 2009 435 442
45. T. Ji, C. Lin, L.S. Krill, R. Eskander, Y. Guo, X. Zi, B. Flavokawain, and et al. a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis Mol. Cancer 12 2013 55
46. B. Li, Y. Yang, S. Jiang, B. Ni, K. Chen, and L. Jiang Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway Int. J. Oncol. 41 2012 1809 1819
47. H. Tazawa, N. Tsuchiya, M. Izumiya, and H. Nakagama Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells Proc. Natl. Acad. Sci. U. S. A. 104 2007 15472 15477
48. Y.Z. Pan, M.E. Morris, and A.M. Yu MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells Mol. Pharmacol. 75 2009 1374 1379
49. Y.Z. Pan, A. Zhou, Z. Hu, and A.M. Yu Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1 Drug Metab. Dispos. 41 2013 1744 1751
50. H. Pelletier, J.M. Millot, B. Chauffert, M. Manfait, P. Genne, and F. Martin Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion Cancer Res. 50 1990 6626 6631
51. K.Y. Choi, O.F. Silvestre, X. Huang, K.H. Min, G.P. Howard, N. Hida, and et al. Versatile RNA interference nanoplatform for systemic delivery of RNAs ACS Nano 8 2014 4559 4570
52. R. Lupertz, W. Watjen, R. Kahl, and Y. Chovolou Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells Toxicology 271 2010 115 121
53. V.G. Desai, J.C. Kwekel, V. Vijay, C.L. Moland, E.H. Herman, T. Lee, and et al. Early biomarkers of doxorubicin-induced heart injury in a mouse model Toxicol. Appl. Pharmacol. 281 2014 221 229